VJOncology is committed to improving our service to you

ASCO 2017 | Combining TKIs with checkpoint inhibitors for prostate cancer – is this the way forward?

VJOncology is committed to improving our service to you

Simon Chowdhury

Simon Chowdury, MD, PhD, from the Sarah Cannon Research Institute, London, UK, talks to us about the undesirable outcomes from research on combining immune checkpoint inhibitors with tyrosine kinase inhibitors (TKIs) for the treatment of prostate cancer, namely hepatoxicity. Although disappointing, he notes that there is still potential for combination therapy in treating prostate cancer. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter